New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:22 EDTRTRX, TXMDRetrophin CEO in scandal over Twitter use, TheStreet reports
Retrophin has placed the company's social media activity on "lockdown" following questionable tweets from CEO Martin Shkreli, including one that seemed to hint at a Retrophin acquisition of an approved drug from a private company, reported TheStreet's Adam Feuerstein. The social media blackout also follows the discovery that employees were using Twitter aliases to promote Retrophin and pitch short-sale recommendations of other stocks, including a tweet that singled out TherapeuticsMD (TXMD), the report added. Reference Link
News For RTRX;TXMD From The Last 14 Days
Check below for free stories on RTRX;TXMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:10 EDTRTRXOn The Fly: Pre-market Movers
Subscribe for More Information
September 16, 2014
17:01 EDTRTRXRetrophin announces CFO Marc Panoff steps down
Retrophin announced that Jeffrey Paley, MD has stepped down as a member of the Board of Directors to more fully devote time to his medical practice, and Marc Panoff has decided to leave his role as CFO to pursue other career opportunities. Panoff will continue overseeing financial operations until a CFO replacement is in place. The company has initiated searches to identify a new independent director and CFO.
September 9, 2014
06:06 EDTRTRXRetrophin files $500M mixed securities shelf

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use